Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder
2010

Impact of Race on Olanzapine Treatment in Schizophrenia

Sample size: 980 publication 10 minutes Evidence: moderate

Author Information

Author(s): Virginia L Stauffer, Jennifer L Sniadecki, Kevin W Piezer, Jennifer Gatz, Sara Kollack-Walker, Vicki Poole Hoffmann, Robert Conley, Todd Durell

Primary Institution: Lilly USA, LLC

Hypothesis

Are there differences in efficacy and safety of olanzapine treatment between white and black patients with schizophrenia?

Conclusion

The study found no significant differences in efficacy or safety between white and black patients treated with olanzapine, although a higher percentage of black patients experienced clinically significant weight gain.

Supporting Evidence

  • 51% of black patients and 45% of white patients discontinued treatment.
  • More white patients discontinued due to psychiatric worsening compared to black patients.
  • A higher percentage of black patients experienced clinically significant weight gain (36.1%) compared to white patients (30.4%).
  • No significant differences in PANSS scores between groups were found.

Takeaway

The study looked at how well a medicine called olanzapine works for black and white people with schizophrenia. It found that both groups had similar results, but more black people gained a lot of weight.

Methodology

A post-hoc, pooled analysis of 6 randomized, double-blind trials comparing white and black patients treated with olanzapine for 24 to 28 weeks.

Potential Biases

The study focused only on patients of black descent primarily from the United States, limiting generalizability.

Limitations

The study was a pooled, posthoc analysis and not prospectively powered to assess efficacy comparisons between racial groups.

Participant Demographics

The study included 605 white patients and 375 black patients, with a mean age of approximately 40 years.

Statistical Information

P-Value

{"discontinuation":0.133,"psychiatric_worsening":0.002,"other_reasons":0.014,"weight_gain":0.021,"efficacy":{"PANSS_total":0.928,"PANSS_positive":0.435,"PANSS_negative":0.756,"CGI_S":0.979}}

Digital Object Identifier (DOI)

10.1186/1471-244X-10-89

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication